Wednesday, July 14, 2021 7:50:40 PM
#Milestones
Recent ITRM News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2024 12:30:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2024 12:15:08 PM
- Iterum Therapeutics Reports Third Quarter 2024 Financial Results • GlobeNewswire Inc. • 11/14/2024 12:00:00 PM
- Iterum Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024 • GlobeNewswire Inc. • 11/11/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/01/2024 09:10:08 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 10/30/2024 10:24:11 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 10/28/2024 10:06:08 AM
- Iterum Therapeutics to Host Morning Conference Call on U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections • PR Newswire (US) • 10/28/2024 09:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/25/2024 03:20:39 PM
- Iterum Therapeutics Receives U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections • GlobeNewswire Inc. • 10/25/2024 03:03:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/15/2024 12:00:08 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 10/11/2024 08:01:41 PM
- Iterum Therapeutics to Present Data at IDWeek 2024 • GlobeNewswire Inc. • 10/10/2024 12:30:00 PM
- Iterum Therapeutics to Participate at the 2024 Maxim Healthcare Virtual Summit • GlobeNewswire Inc. • 10/09/2024 09:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/08/2024 01:15:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/04/2024 09:20:07 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 09/30/2024 08:15:02 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 09/30/2024 11:30:02 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 09/24/2024 01:01:07 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 09/24/2024 12:59:25 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 09/23/2024 10:30:01 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 09/11/2024 08:50:02 PM
- Iterum Therapeutics Provides Update on FDA Advisory Committee Discussion of Oral Sulopenem for the Treatment of uUTI in Adult Women • GlobeNewswire Inc. • 09/10/2024 11:00:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 09/09/2024 10:15:02 AM
- Iterum Therapeutics to Present at the 26th Annual H.C. Wainwright Global Investment Conference • GlobeNewswire Inc. • 09/06/2024 08:30:00 PM
Kona Gold Beverage, Inc. Updates Multi-Million Dollar Merger and Posts Over $1.2 Million in Q3 Revenues • KGKG • Nov 15, 2024 10:36 AM
HealthLynked Corp. Announces Third Quarter and Year-to-Date 2024 Results with Strategic Restructuring, Third-Party Debt Repayment, and Core Technology Focus • HLYK • Nov 15, 2024 8:00 AM
Alliance Creative Group (ACGX) Releases Q3 2024 Financial and Disclosure Report with an increase of over 100% in Net Income for 1st 9 months of 2024 vs 2023 • ACGX • Nov 14, 2024 8:30 AM
Unitronix Corp. Publishes Its Cryptocurrency Portfolio Strategy • UTRX • Nov 14, 2024 8:05 AM
Avant Technologies and Ainnova Tech Form Joint Venture to Advance Early Disease Detection Using Artificial Intelligence • AVAI • Nov 12, 2024 9:00 AM
Swifty Global Announces Launch of Swifty Sports IE, Expanding Sports Betting and Casino Services in the Irish Market • DRCR • Nov 12, 2024 9:00 AM